Metastatic prostate cancer has a unique predilection for bone that can lead to significant clinical sequelae, such as fracture and cord compression.
This tropism for bone yields not only clinical challenges, but also opportunities to understand the tumor biology in bone and to develop relevant therapeutic strategies. The process by which tumor cells migrate to bone, remain dormant, and then colonize and expand is based on complex interactions between prostate cancer tumor cells and the host microenvironment. This review will provide an overview of these interactions as well as therapies targeting osseous metastases in castration-resistant prostate cancer.
Written by:
Autio KA, Morris MJ. Are you the author?
Memorial Sloan-Kettering Cancer Center, New York, New York.
Reference: Clin Adv Hematol Oncol. 2013 Mar;11(3):134-43.
PubMed Abstract
PMID: 23598981
